STAT1 suppresses KRAS Mutated Lung Adenocarcinoma

Lung cancer is a severe disease responsible for the most of cancer-related deaths worldwide. At present, one promising approach to treating lung cancer is the use of immunotherapy, which aims to boost the body`s own immune system to target cancer cells. However, developing effective immunotherapies that work for all patients can be challenging. As part of our efforts to develop better treatments for lung cancer, we have been investigating the role of a genetic mutation in KRAS. This mutation is present in around a third of lung cancer cases and can have a significant impact on the immune response to the cancer. To gain a better understanding of the role of KRAS in lung cancer, we have been studying a protein called STAT1. This protein is involved in regulating the immune response to tumors that carry the KRAS mutation. By uncovering the ways in which KRAS and STAT1 affect the immune response to lung cancer, we hope to develop more personalized and effective treatments for patients. This could lead to improved outcomes and quality of life for those affected by this devastating disease.